CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Earnings & Valuation
This table compares CytomX Therapeutics and Fulcrum Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CytomX Therapeutics | $18.30 million | 27.26 | -$17.37 million | ($0.50) | -4.58 |
| Fulcrum Therapeutics | $80.00 million | 3.60 | -$74.88 million | ($1.21) | -3.12 |
CytomX Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations for CytomX Therapeutics and Fulcrum Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CytomX Therapeutics | 1 | 1 | 9 | 1 | 2.83 |
| Fulcrum Therapeutics | 4 | 7 | 1 | 0 | 1.75 |
CytomX Therapeutics currently has a consensus target price of $11.90, suggesting a potential upside of 419.65%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 117.51%. Given CytomX Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe CytomX Therapeutics is more favorable than Fulcrum Therapeutics.
Profitability
This table compares CytomX Therapeutics and Fulcrum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CytomX Therapeutics | -435.21% | -38.46% | -30.33% |
| Fulcrum Therapeutics | N/A | -25.38% | -24.15% |
Volatility and Risk
CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500.
Summary
Fulcrum Therapeutics beats CytomX Therapeutics on 8 of the 15 factors compared between the two stocks.
About CytomX Therapeutics
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
